CatalystMarker
← board

PBH

distress 0/10 · well-funded / low risk
$48.49-1%today-37% from 52w high
prestigebrands.com890 employeesFounded 1996Tarrytown, NYDrug Manufacturers - Specialty & Generic
Revenue
$1089M
Liquidity
$64M
Runway
Shares 1y
-4%

Price & events

-28.4% over 6M
$45.44$57.82$70.21Jan 26Apr 26Jul 262.5Mfinancing: 8-K material_agreement (2026-07-15)financing: 8-K material_agreement (2026-07-06)financing: 8-K material_agreement (2026-06-16)financing: 8-K material_agreement (2026-05-13)financing: 8-K material_agreement (2026-03-20)rating: Canaccord Genuity: Buy (2026-05-15)rating: Oppenheimer: Outperform → Perform (2026-05-14)rating: Oppenheimer: Outperform (2026-05-07)rating: Jefferies: Hold (2026-02-02)
CatalystRating changeDilutionFinancingdashed = today
-1.1%
1D
-4.2%
1W
+5.3%
1M
-16.1%
3M
-26.3%
6M
-36.8%
1Y
-31.6%
2Y
-7.8%
5Y
+34.1%
All

Overview

Market Cap
$2.30B
Enterprise Value
$3.23B
Volume
15.49K
52 Week Range
$45.44 – $76.88
Total Shares
47.37M
Float Shares
46.69M
Short %
8.18%
% Held by Insiders
1.38%
% Held by Institutions
113.97%
RVOL
0.02x
Beta
0.35

Pipeline · 0 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
No pipeline trials tracked.

Catalyst news & presentations · 3

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 47,372,166 · 0 offerings/1y · 0 PIPEs
  • 2026-07-158-Kmaterial_agreement
  • 2026-07-068-Kmaterial_agreement
  • 2026-06-168-Kmaterial_agreement
  • 2026-05-138-Kmaterial_agreement
  • 2026-03-208-Kmaterial_agreement
  • 2025-08-078-Kmaterial_agreement
  • 2024-11-08SC 13G/Astrategic_stake
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

no consensus
  • 2026-05-15Canaccord GenuityBuy
  • 2026-05-14OppenheimerOutperform → Perform
  • 2026-05-07OppenheimerOutperform
  • 2026-02-02JefferiesHold
  • 2025-11-07Canaccord GenuityBuy
  • 2025-10-27JefferiesHold

Competitors

  • none identified

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.